Download MendeleyDiscovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy.
Zhang, Z., Ding, Q., Liu, J.J., Zhang, J., Jiang, N., Chu, X.J., Bartkovitz, D., Luk, K.C., Janson, C., Tovar, C., Filipovic, Z.M., Higgins, B., Glenn, K., Packman, K., Vassilev, L.T., Graves, B.(2014) Bioorg Med Chem 22: 4001-4009
- PubMed: 24997575
- DOI: https://doi.org/10.1016/j.bmc.2014.05.072
- Primary Citation of Related Structures:
4LWT, 4LWU - PubMed Abstract:
The field of small-molecule inhibitors of protein-protein interactions is rapidly advancing and the specific area of inhibitors of the p53/MDM2 interaction is a prime example. Several groups have published on this topic and multiple compounds are in various stages of clinical development. Building on the strength of the discovery of RG7112, a Nutlin imidazoline-based compound, and RG7388, a pyrrolidine-based compound, we have developed additional scaffolds that provide opportunities for future development. Here, we report the discovery and optimization of a highly potent and selective series of spiroindolinone small-molecule MDM2 inhibitors, culminating in RO8994.
Organizational Affiliation:
Discovery Chemistry, Roche Research Center, Hoffmann-La Roche, Inc., 340 Kingsland Street, Nutley, NJ 07110, United States. Electronic address: zzhang85@its.jnj.com.
